Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NEK2 | P51955 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14611417 | 0.85 | ALDH1A1 (0.40) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14382124 | 0.85 | ALDH1A1 (0.40) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12616491 | 0.85 | ALDH1A1 (0.40) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18845660 | 0.82 | GABRR1 (0.34) | ALDH1A1 | |
| SCHEMBL18842320 | 0.82 | GABRR1 (0.34) | ALDH1A1 | |
| SCHEMBL18845617 | 0.82 | GABRR1 (0.34) | ALDH1A1 | |
| SCHEMBL18842330 | 0.82 | GABRR1 (0.34) | ALDH1A1 | |
| SCHEMBL15592009 | 0.79 | ALDH1A1 (0.40) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14569618 | 0.78 | ALDH1A1 (0.46) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19010968 | 0.76 | AKR1C4 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951793-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7279485-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | PYM1, GPR119, GLP1R | ALDH1A1 4235/4885NEK2 3511/4885SLC6A2 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.